|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-7-21
|
|
pubmed:abstractText |
Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double-blind, randomized, placebo-controlled phase I studies, postmenopausal female subjects received odanacatib (ODN), an orally active, potent, and selective CatK inhibitor, once weekly for 3 weeks or once daily for 21 days. Bone turnover biomarkers, safety monitoring, and plasma ODN concentrations were assessed. These studies showed ODN to be well tolerated. Pharmacokinetic (PK) analysis revealed a long half-life (t(1/2); 66-93 h) consistent with once-weekly dosing. Pronounced reductions in C-terminal telopeptide of type I collagen (approximately 62%) and N-terminal telopeptide of type I collagen normalized to creatinine (NTx/Cr) (approximately 62%) at trough (C(168 h)) were seen following weekly administration. Robust reductions in CTx (up to 81%) and NTx/Cr (up to 81%) were seen following daily administration. ODN exhibits robust and sustained suppression of bone resorption biomarkers (CTx and NTx/Cr) at weekly doses > or = 25 mg and daily doses > or = 2.5 mg.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Biphenyl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/CTSK protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cathepsin K,
http://linkedlifedata.com/resource/pubmed/chemical/Cathepsins,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Procollagen,
http://linkedlifedata.com/resource/pubmed/chemical/collagen type I trimeric...,
http://linkedlifedata.com/resource/pubmed/chemical/odanacatib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1532-6535
|
|
pubmed:author |
pubmed-author:De DeckerMM,
pubmed-author:DuongL TLT,
pubmed-author:GottesdienerKK,
pubmed-author:GutierrezM JMJ,
pubmed-author:JieKK,
pubmed-author:LieAA,
pubmed-author:LiuLL,
pubmed-author:MillerD LDL,
pubmed-author:PanebiancoDD,
pubmed-author:ScottB BBB,
pubmed-author:StochS ASA,
pubmed-author:StoneJJ,
pubmed-author:Van DyckKK,
pubmed-author:WagnerJ AJA,
pubmed-author:ZajicSS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
175-82
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19421185-Administration, Oral,
pubmed-meshheading:19421185-Aged,
pubmed-meshheading:19421185-Biological Markers,
pubmed-meshheading:19421185-Biphenyl Compounds,
pubmed-meshheading:19421185-Bone Resorption,
pubmed-meshheading:19421185-Cathepsin K,
pubmed-meshheading:19421185-Cathepsins,
pubmed-meshheading:19421185-Collagen Type I,
pubmed-meshheading:19421185-Double-Blind Method,
pubmed-meshheading:19421185-Drug Administration Schedule,
pubmed-meshheading:19421185-Female,
pubmed-meshheading:19421185-Humans,
pubmed-meshheading:19421185-Middle Aged,
pubmed-meshheading:19421185-Osteoporosis, Postmenopausal,
pubmed-meshheading:19421185-Peptide Fragments,
pubmed-meshheading:19421185-Peptides,
pubmed-meshheading:19421185-Procollagen,
pubmed-meshheading:19421185-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
|
|
pubmed:affiliation |
Merck Research Laboratories, Rahway, New Jersey, USA. aubrey_stoch@merck.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
